Spring offer! Get NewsNow Essentials at just £2.99 a month (40% OFF!). Faster, slicker, customisable & ad free!Spring offer! Get NewsNow Essentials at just £2.99 a month (40% OFF!). Go ad free today!Spring offer! Upgrade now at £2.99/m (40% OFF!)

Home
Hot Topics
UK
World
Gaza
Ukraine
Iran
Climate Crisis
Business
Football
Sport
Entertainment
Tech
Science

Biogen
Biotech
AbbVie
Topics

Advertisement

Biogen

Share

Top Latest Popular

🗞️ NEWSNOW ESSENTIALS | Support independent news discovery ad free at just £2.99/m!

🗞️ NEWSNOW ESSENTIALS | Support independent news discovery ad free at just £2.99 a month!

Yesterday

Biogen investigated by Italian regulator over multiple sclerosis ‘market abuse’ claims FiercePharma 12:40 Wed, 27 May

Italy probes Biogen for allegedly hindering sales of rival's MS drug The Tribune, California 09:55 Wed, 27 May

Italy's antitrust regulator opens probe into US Biogen over alleged dominant position Rock Hill Herald 07:50 Wed, 27 May

Advertisement

Advertisement

Monday

Biogen and Denali discontinue Parkinson’s candidate BIIB122 after Phase IIb LUMA study miss Manufacturing Chemist 08:07 Mon, 25 May

Friday

Denali Stock Dips as Biogen-Partnered Parkinson's Disease Study Fails Zacks 18:17 Fri, 22 May

Biogen, Denali Discontinue BIIB122 Development In Idiopathic Parkinson’s After Phase IIb Miss Scrip Pharma Intelligence 15:08 Fri, 22 May

Biogen and Denali report Phase IIb LUMA trial data for Parkinson’s Clinical Trials Arena 11:40 Fri, 22 May

Biogen And Denali Halt Development Of BIIB122 After Phase 2b Luma Study Misses Key Goals RTT News 09:19 Fri, 22 May

Biogen, Denali pull Parkinson's drug after failed trial pharmaphorum 08:57 Fri, 22 May

Biogen, Denali scrap Parkinson's drug after failure in mid-to-late stage study Rock Hill Herald 08:25 Fri, 22 May

In the last month

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biogen Inc. - BIIB PR Newswire (Press Release) 23:45 Thu, 21 May

Biogen and Denali Therapeutics Provide Update on Phase 2b LUMA Study of BIIB122 (DNL151) in Early-Stage Parkinson’s Disease Biogen (Press Release) 23:07 Thu, 21 May

Biogen Patent Suit Targets Somerset’s Copy of Spinraza Therapy Bloomberg Law 21:36 Thu, 21 May

Apellis soars on Biogen deal as biopharma index trails the market BioWorld 21:33 Thu, 21 May

Are Wall Street Analysts Bullish on Biogen Stock? Barchart 13:47 Wed, 20 May

Advertisement

BIIB Investor Alert: Levi & Korsinsky Investigates Biogen Inc. (BIIB) for Potential Securities Fraud Business Wire (Press Release) 21:07 Tue, 19 May

Immunic appoints Biogen, Cubist veteran Mike Bonney as board chair ahead of key MS trial readout Proactive Investors (US) 14:38 Tue, 19 May

Goldman Sachs raises Biogen price target to $250 on Leqembi surge Lexington Herald-Leader, Kentucky 18:47 Sun, 17 May

BIIB Advances Alzheimer's Disease Drug Despite Study Missing Main Goal Zacks 17:32 Fri, 15 May

Biogen forges on with Alzheimer’s therapy development despite Phase II miss Clinical Trials Arena 11:41 Fri, 15 May

Inside Biotech: Biogen’s Alzheimer’s setback still points to a bigger shift in the field Proactive Investors (Australia) 06:33 Fri, 15 May

Biogen Pharmachem Industries reports standalone net loss of Rs 0.36 crore in the March 2026 quarter The Business Standard 04:38 Fri, 15 May

The ADDF Highlights Encouraging Progress Toward Targeting Multiple Alzheimer's Pathologies in Biogen's Phase 2 Tau Study PR Newswire (Press Release) 01:50 Fri, 15 May

Biogen Justifies Phase III Trial For Anti-Tau Drug Despite Phase II Miss Scrip Pharma Intelligence 00:31 Fri, 15 May

Biogen advances Alzheimer’s drug on suggestion of benefit Boston Globe 23:28 Thu, 14 May

Biogen AD drug shows tau, cognition benefit, despite trial miss BioWorld 22:23 Thu, 14 May

Best Healthcare Stocks to Buy in 2026 The Motley Fool 20:00 Thu, 14 May

Trial miss doesn't dent Biogen's faith in Alzheimer's drug pharmaphorum 16:57 Thu, 14 May

Biogen Completes Acquisition of Apellis Pharmaceuticals Biogen (Press Release) 13:44 Thu, 14 May

STAT Plus: Biogen’s tau-targeting Alzheimer’s drug posts mixed results in mid-stage study STAT 12:12 Thu, 14 May

Topline Results from Phase 2 CELIA Study of Diranersen (BIIB080): First Study to Show Reduction in Tau Pathology and Cognitive Benefit in Patients with Early Alzheimer’s Disease Biogen (Press Release) 12:02 Thu, 14 May

FDA Extends Review of Eisai, Biogen Alzheimer's Drug IBTimes (US) 15:13 Sat, 09 May

Eisai, Biogen face delay to subcutaneous Leqembi pharmaphorum 13:23 Fri, 08 May

Alteogen posts strong Q1 earnings on GSK, Biogen licensing deals Korea Biomedical Review 09:08 Fri, 08 May

Update on FDA Priority Review of LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection as a Starting Dose for Early Alzheimer’s Disease Biogen (Press Release) 07:35 Fri, 08 May

Biogen to Participate in the Bank of America Securities 2026 Health Care Conference Biogen (Press Release) 21:18 Tue, 05 May

Bristol Myers’ legacy lift, Biogen’s blue skies and Regeneron’s murky outlook BioPharma Dive 15:54 Fri, 01 May

Biogen Analysts Boost Their Forecasts Following Upbeat Q1 Earnings Benzinga 17:00 Thu, 30 Apr

Biogen agrees $850m felzartamab rights deal with TJ Biopharma PMLiVE 10:53 Thu, 30 Apr

Why Biogen Stock Was a Winner on Wednesday The Motley Fool 01:00 Thu, 30 Apr

Advertisement

Advertisement

About our Biogen News

Biogen is an American multinational biotechnology company that specialises in treatment of neurological diseases.

NewsNow

Our Sites

NewsNow Nigeria

NewsNow România

NewsNow Australia

Work with us

Publisher Network

Dockside Online IDE

Legal

Subscription Terms

© Copyright 1997 - 2026 NewsNow Publishing Limited. All rights reserved.

Biotech Biotech
Back to Industry Sectors Biotech
- GM Food GM Food
- AbbVie AbbVie
- Amgen Amgen
- Biogen Biogen
- BioNTech BioNTech
- Celltrion Celltrion
- Genentech Genentech
- Gilead Sciences
- Illumina Illumina
- Moderna Moderna